Clinical trial
A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)
NCT00078312 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Study of the Safety and Efficacy of CEP-10953 in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)
- Lead sponsor
- Cephalon
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- July 31, 2006
- Enrollment
- 328 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.
narcolepsy, shift-work sleep disorder, sleep apnea syndromes, sleep apnea, obstructive